Phase 1 N=72 Assessment of the Human Systemic Absorption of Sunscreen Ingredients
Systemic Exposure to Sunscreen Ingredients
Primary: Avobenzone Maximum Concentration — 1.8; 4.3; 4.0; 3.4 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Skin Cancer
Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 3 N=10 Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)
Sun Protection
Primary: Determination of Sunscreen Protection Factor (SPF) — 14.72; 15.00 Score on a scale
N/A N=164 UV Exposure Assessed With Wearable Sensor and Sun Protection
Sunburn, Erythema · Sun Protection
Primary: Acceptability of Wearing UV Sensor and Receiving Text Messages — 22; 39.1; 40.1; 40.6 score on a scale — p=<0.01
N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
N/A N=15 Clinical Study to Evaluate the 80-Minute Water Resistant Sun Protection Factor (SPF) of Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values
N/A N=8 A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations
Sunscreening Agents
Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values — 33.1; 35.2; 35.2; 45.2 Ratio
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
N/A N=13 Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values — 29.2; 16.4; 28.2; 16.4 Ratio
Phase 1 N=38 Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment
Healthy
Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale
N/A N=41 Using Physical Tracking to Predict Sunburn
Prevention
Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day
Phase 3 N=137 Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
N/A N=11 Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values — 13.9; 16.1; 14.3; 15.8 Ratio
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
Early Phase 1 N=70 Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
Skin Cancer
Primary: Number of Days the Subjects Are Adherent to Using Sunscreen — 12.6; 23.6 days
Phase 2 N=33 Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
Molluscum Contagiosum
Primary: The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following…
N/A N=26 Determination of the Sun Protection Factor (SPF) of a Cosmetic Daily De-fence Skin Cream
Sunscreening Agents
Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Value — 19.4; 14.0 Ratio (unit less)
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
Phase 1 N=35 Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
Phototoxicity
Primary: Within-subject Comparison and Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation), After Application of MC2-01 Cream…
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
N/A N=36 To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale
Phase 2 N=14 Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
Keratosis, Actinic
Primary: Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA — 39.05 ng/mL
N/A N=31 An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light
Sun Damaged Skin
Primary: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression From Baseline (Pre-solar Stimulated Light Exposure to 1 and 24 Hours Post Exposure)…
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
Phase 1 N=34 A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
Healthy
Primary: Observed Phototoxicity — 0.15; 0.15; 0.00; 0.00 Score on a scale — p=1.0000
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale